MedTrace Logo

Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care

NCT07359287 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4500

Last updated 2026-01-22

No results posted yet for this study

Summary

Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common.

We are proposing a cluster-randomized controlled trial to evaluate the effectiveness of a bimodal intervention combining: (1) improved communication about the circulation of respiratory viruses, and (2) strengthened collaborative practices between general practitioners and pharmacists through a multidisciplinary protocol aimed at verifying that prescribed treatment durations comply with guidelines.

The study will include six primary care practices (24 physicians), with three practices in each study arm.

The aim of this project is to assess whether the bimodal intervention can reduce the duration of antibiotic treatments for upper and lower respiratory tract infections. The first component (a "viral infection prescription" tool) focuses on reducing unnecessary treatment initiation, while the second (pharmacist-led review) aims to shorten excessive prescription durations.

Conditions

  • Angina
  • Acute Bronchiolitis
  • Acute Bronchitis
  • COPD Exacerbation (AECOPD)
  • Laryngitis
  • Acute Otitis Media (AOM)
  • Serous or Congestive Otitis
  • Viral Respiratory Infection (e.g., Influenza)
  • Community-Acquired Pneumonia (CAP)
  • Rhinitis / Nasopharyngitis
  • Acute Sinusitis

Interventions

OTHER

Antibiotic prescribing according to guidelines

If necessary, the general practitioner prescribes antibiotics to patients consulting for an upper or lower respiratory tract infection, according to the guidelines.

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-06-01
Completion
2026-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07359287 on ClinicalTrials.gov